Charles Schwab Investment Management Inc Viracta Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $41,267 - $70,726	12,430 New	12,430 $54,000
Q2 2022 Aug 15, 2022	SELL	$1.87 - $5.0 $147,950 - $395,590	-79,118 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.23 - $4.76 $15,480 - $33,043	-6,942 Reduced 8.07%	79,118 $377,000
Q3 2021 Nov 16, 2021	BUY	$7.84 - $12.53 $17,781 - $28,418	2,268 Added 2.71%	86,060 $691,000
Q2 2021 Aug 16, 2021	BUY	$7.55 - $12.95 $632,629 - $1.09 Million	83,792 New	83,792 $951,000

5.63M

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $9.39M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.